Abstract
When cells experience hypoxia, they either die by apoptosis or adapt to the hypoxic conditions by a series of compensatory mechanisms. Hypoxia inducible factor-1 (HIF-1) is a transcription factor involved in both processes, but the exact mechanisms regulating whether the cells survive (adapt) or perish by apoptosis are largely unknown.
We hypothesize that the balancing between apoptosis and adaptation is governed by a triangular feedback system involving the α-subunit of HIF-1, p53, and jun activating binding protein 1 (Jab1). Jab1 and p53 bind competitively to the same domain on HIF-1α resulting in either stabilization or degradation of HIF-1α, respectively. Moreover, p53 is stabilized by binding to HIF-1α, whereas its interaction with Jab1 targets p53 for degradation. Thus as a consequence we propose that the ratio between p53 and Jab1 determine whether a hypoxic induction of HIF-1 results in apoptosis or adaptation, with Jab1 as the factor promoting adaptation. On this background we consider Jab1 an interesting molecular target for anticancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Ivan, and W. G. Kaelin, Jr., The von Hippel-Lindau tumor suppressor protein, Curr. Opin. Genet. Dev. 11, 27–34 (2001).
K. Kondo and W. G. Kaelin, Jr., The von Hippel-Lindau tumor suppressor gene, Exp. Cell Res. 264, 117–125 (2001).
J. M. Brown, Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies, Mol. Med. Today 6, 157–162 (2000).
G. L. Semenza, HIF-1 and mechanisms of hypoxia sensing, Curr. Opin. Cell Biol. 13, 167–171 (2001).
G. L. Semenza, Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease, Pediatr. Res. 49, 614–617 (2001).
G. L. Semenza, HIF-1: mediator of physiological and pathophysiological responses to hypoxia, J. Appl. Physiol 88, 1474–1480 (2000).
P. Carmeliet, Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen, E. Keshert, and E. Keshet, Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis, Nature 394, 485–490 (1998).
R. K. Bruick, Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia, Proc. Natl. Acad. Sci. USA 97, 9082–9087 (2000).
W. G. An, M. Kanekal, M. C. Simon, E. Maltepe, M. V. Blagosklonny, and L. M. Neckers, Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha, Nature 392, 405–408 (1998).
H. Suzuki, A. Tomida, and T. Tsuruo, Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia, Oncogene 20, 5779–5788 (2001).
D. Chen, M. Li, J. Luo, and W. Gu, Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function, J. Biol. Chem. 278, 13595–13598 (2003).
S. Salceda, I. Beck, V. Srinivas, and J. Caro, Complex role of protein phosphorylation in gene activation by hypoxia, Kidney Int. 51, 556–559 (1997).
P. Jaakkola, D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science 292, 468–472 (2001).
E. Minet, T. Arnould, G. Michel, I. Roland, D. Mottet, M. Raes, J. Remacle, and C. Michiels, ERK activation upon hypoxia: involvement in HIF-1 activation, FEBS Lett. 468, 53–58 (2000).
D. E. Richard, E. Berra, E. Gothie, D. Roux, and J. Pouyssegur, p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1 alpha) and enhance the transcriptional activity of HIF-1, J. Biol. Chem. 274, 32631–32637 (1999).
D. Lando, D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw, Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch, Science 295, 858–861 (2002).
M. K. Bae, M. Y. Ahn, J. W. Jeong, M. H. Bae, Y. M. Lee, S. K. Bae, J. W. Park, K. R. Kim, and K. W. Kim, Jab1 interacts directly with HIF-1alpha and regulates its stability, J. Biol. Chem. 277, 9–12 (2002).
R. Ravi, B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi, Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha, Genes Dev. 14, 34–44 (2000).
M. V. Blagosklonny, W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers, p53 inhibits hypoxia-inducible factor-stimulated transcription, J. Biol. Chem. 273, 11995–11998 (1998).
L. O. Hansson, A. Friedler, S. Freund, S. Rudiger, and A. R. Fersht, Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53, Proc. Natl. Acad. Sci. USA 99, 10305–10309 (2002).
F. X. Claret, M. Hibi, S. Dhut, T. Toda, and M. Karin, A new group of conserved coactivators that increase the specificity of AP-1 transcription factors, Nature 383, 453–457 (1996).
S. F. Kwok, R. Solano, T. Tsuge, D. A. Chamovitz, J. R. Ecker, M. Matsui, and X. W. Deng, Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex, and their abundance is differentially affected by the pleiotropic cop/det/fus mutations, Plant Cell 10, 1779–1790 (1998).
M. H. Glickman, D. M. Rubin, O. Coux, I. Wefes, G. Pfeifer, Z. Cjeka, W. Baumeister, V. A. Fried, and D. Finley, A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3, Cell 94, 615–623 (1998).
D. Bech-Otschir, R. Kraft, X. Huang, P. Henklein, B. Kapelari, C. Pollmann, and W. Dubiel, COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system, EMBO J. 20, 1630–1639 (2001).
M. Seeger, R. Kraft, K. Ferrell, D. Bech-Otschir, R. Dumdey, R. Schade, C. Gordon, M. Naumann, and W. Dubiel, A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits, FASEB J. 12, 469–478 (1998).
K. Tomoda, Y. Kubota, and J. Kato, Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1, Nature 398, 160–165 (1999).
K. Tomoda, Y. Kubota, Y. Arata, S. Mori, M. Maeda, T. Tanaka, M. Yoshida, N. Yoneda-Kato, and J. Y. Kato, The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex, J. Biol. Chem. 277, 2302–2310 (2002).
L. B. Gardner, Q. Li, M. S. Park, W. M. Flanagan, G. L. Semenza, and C. V. Dang, Hypoxia inhibits G1/S transition through regulation of p27 expression, J. Biol. Chem. 276, 7919–7926 (2001).
N. Goda, H. E. Ryan, B. Khadivi, W. McNulty, R. C. Rickert, and R. S. Johnson, Hypoxia-inducible factor 1 alpha is essential for cell cycle arrest during hypoxia, Mol. Cell Biol. 23, 359–369 (2003).
R. M. Gemmill, L. T. Bemis, J. P. Lee, M. A. Sozen, A. Baron, C. Zeng, P. F. Erickson, J. E. Hooper, and H. A. Drabkin, The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway, Oncogene 21, 3507–3516 (2002).
T. G. Graeber, J. F. Peterson, M. Tsai, K. Monica, A. J. Fornace, Jr., and A. J. Giaccia, Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status, Mol. Cell Biol. 14, 6264–6277 (1994).
T. G. Graeber, C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379, 88–91 (1996).
E. M. Hammond, N. C. Denko, M. J. Dorie, R. T. Abraham, and A. J. Giaccia, Hypoxia links ATR and p53 through replication arrest, Mol. Cell Biol. 22, 1834–1843 (2002).
E. M. Hammond, M. J. Dorie, and A. J. Giaccia, ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to re-oxygenation, J. Biol. Chem. 278(14), 12207–12213 (2003).
M. Achison and T. R. Hupp, Hypoxia attenuates the p53 response to cellular damage, Oncogene 22, 3431–3440 (2003).
R.H. Wenger, G. Camenisch, I. Desbaillets, D. Chilov, and M. Gassmann, Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction, Cancer Res. 58, 5678–5680(1998).
K. L. Talks, H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. L. Harris, The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages, Am. J. Pathol. 157, 411–421 (2000).
K. L. Sondergaard, D. A. Hilton, M. Penney, M. Ollerenshaw, and A. G. Demaine, Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma, Neuropathol. Appl. Neurobiol. 28, 210–217 (2002).
H. Zhong, A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza, and J. W. Simons, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases, Cancer Res. 59, 5830–5835 (1999).
G. L. Semenza, Hypoxia, clonal selection, and the role of HIF-1 in tumor progression, Crit Rev. Biochem. Mol. Biol. 35, 71–103 (2000).
P. Birner, M. Schindl, A. Obermair, C. Plank, G. Breitenecker, and G. Oberhuber, Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer, Cancer Res. 60, 4693–4696 (2000).
D. M. Aebersold, P. Burri, K. T. Beer, J. Laissue, V. Djonov, R. H. Greiner, and G. L. Semenza, Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer, Cancer Res. 61, 2911–2916 (2001).
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, C. Simopoulos, H. Turley, K. Talks, K. C. Gatter, and A. L. Harris, Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer, Int. J. Radiat. Oncol. Biol. Phys. 53, 1192–1202 (2002).
A. Unruh, A. Ressel, H. G. Mohamed, R. S. Johnson, R. Nadrowitz, E. Richter, D. M. Katschinski, and R. H. Wenger, The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy, Oncogene 12, 3213–3220 (2003).
P. Birner, B. Gatterbauer, G. Oberhuber, M. Schindl, K. Rossler, A. Prodinger, H. Budka, and J. A. Hainfellner, Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis, Cancer 92, 165–171 (2001).
L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, Y. Tai, and M. Tokuda, Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors, Clin. Cancer Res. 7, 4130–4135 (2001).
M.A. Kouvaraki, G. Z. Rassidakis, L. Tian, R. Kumar, C. Kittas, and F. X. Claret, Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1), Cancer Res. 63, 2977–2981 (2003).
A. J. Levine, p53, the cellular gatekeeper for growth and division, Cell 88, 323–331 (1997).
J. L. Yu, J. W. Rak, B. L. Coomber, D. J. Hicklin, and R. S. Kerbel, Effect of p53 status on tumor response to antiangiogenic therapy, Science 295, 1526–1528 (2002).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Larsen, M., Høg, A., Lund, E.L., Kristjansen, P.E.G. (2005). Interactions between HIF-1 and Jab1: Balancing Apoptosis and Adaptation. In: Okunieff, P., Williams, J., Chen, Y. (eds) Oxygen Transport to Tissue XXVI. Advances in Experimental Medicine and Biology, vol 566. Springer, Boston, MA. https://doi.org/10.1007/0-387-26206-7_28
Download citation
DOI: https://doi.org/10.1007/0-387-26206-7_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25062-5
Online ISBN: 978-0-387-26206-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)